サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1577521

虚血性心疾患（IHD）治療薬の世界市場

Ischemic Heart Disease (IHD) Drugs

出版日
ページ情報
英文 194 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.79円
虚血性心疾患（IHD）治療薬の世界市場
出版日: 2024年10月25日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

虚血性心疾患（IHD）治療薬の世界市場は2030年までに72億米ドルに到達

2023年に61億米ドルと推定される虚血性心疾患（IHD）治療薬の世界市場は、分析期間2023-2030年にCAGR 2.4%で成長し、2030年には72億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである狭心症治療薬は、CAGR 2.6%を記録し、分析期間終了時には43億米ドルに達すると予測されます。心筋梗塞治療薬セグメントの成長率は、分析期間中CAGR 2.0%と推定されます。

米国市場は17億米ドル、中国はCAGR 4.8％で成長すると予測

米国の虚血性心疾患（IHD）治療薬市場は2023年に17億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに14億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは4.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.6%と1.7%と予測されています。欧州では、ドイツがCAGR 1.1%で成長すると予測されています。

世界の虚血性心疾患（IHD）治療薬市場- 主要動向と促進要因のまとめ

虚血性心疾患（IHD）治療薬が心血管ヘルスケアで重要な焦点になりつつあるのはなぜか？

冠動脈疾患としても知られる虚血性心疾患（IHD）は、依然として世界の罹患率および死亡率の主要原因の一つであり、効果的な治療ソリューションに対する大きな需要を牽引しています。IHDは、心筋への血液供給の減少を特徴とし、多くの場合、冠動脈にプラークが蓄積することによって引き起こされ、胸痛（狭心症）、息切れ、重症の場合は心臓発作などの症状を引き起こします。人口の高齢化、座りがちなライフスタイル、高血圧、糖尿病、肥満などの危険因子の増加などの要因により、IHDの有病率は増加しており、IHD治療薬は心血管医療の重要な要素となっています。IHDの世界の負担が増大し続ける中、IHDを効果的に管理し、患者の予後を改善し、生命を脅かす心イベントのリスクを低減する薬物療法の開発と最適化に注目が集まっています。

IHD治療薬の市場は、世界中のヘルスケアシステムが心血管系の健康を優先するにつれて拡大しています。IHDの主な治療薬には、抗血小板薬、抗凝固薬、β遮断薬、カルシウム拮抗薬、硝酸薬、脂質低下薬などがあります。これらの薬剤は、症状を緩和し、合併症を予防し、患者の生活の質を高めることを目的としています。最近の研究開発動向では、PCSK9阻害薬やGLP-1受容体作動薬など、高コレステロール血症や糖尿病などの根本的な危険因子に対処することにより、さらなる治療効果をもたらす新規薬剤クラスをターゲットとした研究が急増しています。個別化医療が重視されるようになったことで、IHD治療薬市場もさらに影響を受けています。遺伝的、生化学的、生活習慣的要因に基づく個々の患者プロファイルに合わせた治療アプローチがますます増えているからです。その結果、より効果的で個別化されたIHD治療薬への需要が、世界市場の革新と成長を促進しています。

IHD治療薬の将来を形作る技術的・薬理学的イノベーションとは？

技術的・薬理学的進歩はIHD治療薬開発の状況を大きく変え、より効果的で安全な治療法の導入につながっています。主な技術革新の一つは、IHDに関連する特定の生物学的経路を標的とする新規薬剤クラスの開発です。例えば、アリロクマブやエボロクマブのようなPCSK9阻害剤は、従来のスタチン療法に反応しない患者のLDLコレステロール値を大幅に低下させる画期的な脂質低下剤として登場しました。PCSK9タンパク質を阻害することにより、これらの薬剤はLDLコレステロールを血流から除去する肝臓の能力を高め、心血管イベントのリスクを低下させる。もう一つの有望な薬剤クラス別はSGLT-2阻害薬で、もともとは糖尿病管理のために開発されたものであるが、IHD患者において心保護作用を示し、心不全や心筋梗塞のリスクを低下させています。このような薬理学的進歩により、IHDの治療に利用できる選択肢の幅が広がり、臨床医はより包括的で的を絞った治療戦略を採用できるようになっています。

さらに、ドラッグデリバリー技術の進歩により、IHD治療薬の有効性と患者のコンプライアンスが向上しています。徐放性製剤、経皮パッチ、併用療法の使用は、薬物吸収の最適化と投与回数の減少に役立っており、それにより治療レジメンに対する患者のアドヒアランスが向上しています。さらに、創薬・開発における人工知能（AI）と機械学習の統合は、新たな治療ターゲットの同定と臨床試験デザインの最適化を加速させています。AI主導のプラットフォームは、膨大なデータセットを解析して薬剤の有効性と安全性プロファイルを予測し、より効率的な薬剤開発プロセスを可能にします。薬理ゲノミクスの活用も新たなトレンドのひとつで、薬物反応に影響を与える遺伝子マーカーを特定することで、個々の患者の遺伝子構成に合わせた個別化治療への道を開くことができます。このような技術的・薬理学的革新は、IHD治療薬の開発分野を前進させるだけでなく、治療をより効果的で安全なものにし、より多くの患者さんが利用できるようにするものです。

市場力学とヘルスケア政策は虚血性心疾患治療薬市場にどのような影響を与えているか？

虚血性心疾患治療薬の世界市場は、地域によって大きく異なる市場力学とヘルスケア政策の組み合わせによって形成されています。特に北米や欧州のような高齢化とライフスタイルに関連した危険因子が蔓延している先進地域では、IHDの有病率が増加しており、これが市場成長の主な要因となっています。また、アジア太平洋やラテンアメリカなどの新興国市場でも、経済開拓や都市化、食生活の変化が心血管疾患の負担増につながっており、IHD治療薬に対する需要が高まっています。こうした動向を受けて、製薬企業はこれらの地域でのプレゼンスを拡大し、現地の生産施設に投資し、地域のヘルスケアプロバイダーと提携して、IHD治療薬へのアクセスを改善しようとしています。

ヘルスケア政策と償還の枠組みも、IHD治療薬市場の形成に重要な役割を果たしています。多くの国では、IHD治療薬の費用は公的または民間の保険制度でカバーされており、これらの治療薬は患者にとってより利用しやすいものとなっています。しかし、特に生物学的製剤や専門薬のような新しい治療薬の価格が上昇しているため、購入可能な価格やアクセスに関する懸念が高まっています。欧州のようにヘルスケア予算が厳しい地域では、政府や医療機関が価格交渉、基準価格設定、ジェネリック医薬品やバイオシミラー医薬品の普及促進などのコスト抑制策を実施しています。こうした政策は製薬会社の価格戦略に影響を与え、費用対効果の高い治療法の採用を促進しています。さらに、米国食品医薬品局（FDA）や欧州医薬品庁（EMA）などの規制当局は、新しいIHD治療薬の承認と償還を裏付ける臨床エビデンスと実臨床データの重要性を強調しています。このような規制状況により、企業はより厳密な臨床試験と市販後試験を実施し、新薬が既存の治療と比較して有意義なベネフィットをもたらすことを確実にするよう求められています。

バリュー・ベース・ヘルスケアの推進も、IHD治療薬市場に影響を与える要因の一つです。医療制度は、優れた有効性、安全性、費用対効果を示す治療を優先するアウトカムベースのアプローチをますます重視するようになっています。このシフトにより、製薬会社は自社製品の価値を実証するために長期臨床試験や医療経済学的研究に投資するようになっています。さらに、予防医療と危険因子の管理が重視されるようになったことで、疾患の治療だけでなく、高血圧、糖尿病、高コレステロールなどの基礎疾患にも対応するIHD治療薬の開発が形成されつつあります。このような市場力学と政策動向は、IHD治療薬市場に課題と機会の両方を生み出しています。利害関係者は、技術革新とコスト抑制や医療へのアクセスのバランスを模索しているからです。

虚血性心疾患治療薬市場の拡大を促進する主な成長要因は？

世界の虚血性心疾患（IHD）治療薬市場の成長は、心血管疾患の有病率の増加、新規薬物療法の市場開拓、個別化医療や予防医療への注目の高まりなど、いくつかの主な要因によってもたらされます。主な成長要因の1つは、肥満、糖尿病、高血圧、座りがちなライフスタイルなどの危険因子と密接に関連するIHDの発症率の上昇です。人口の高齢化と生活習慣病の蔓延に伴い、IHDの世界の負担は増加の一途をたどると予想されます。このような患者数の増加が、症状を管理し、合併症を予防し、心臓発作などの急性イベントのリスクを低減できる効果的なIHD治療に対する需要を促進しています。さらに、心血管系の健康に対する意識の高まりと早期介入の重要性は、より多くの患者が医師の診断を受け、処方された治療を遵守することを促し、IHD治療薬の需要をさらに押し上げています。

もう一つの重要な成長要因は、新たな作用機序と安全性プロファイルを改善した新規薬物療法の開発と商業化が進んでいることです。最近のIHDの病態生理に関する理解の動向は、IHDに関与する特定の分子経路を標的とする革新的な薬剤の開発につながっています。例えば、PCSK9阻害薬やSGLT-2阻害薬のイントロダクションは、IHDを管理するための治療法を拡大し、従来の治療法では十分にコントロールできない患者に選択肢を提供しています。また、複数の経路を同時に標的とする併用療法の開発も、単剤療法に比べて有効性と利便性を高めることができるため、注目を集めています。さらに、個々の遺伝的・臨床的プロファイルに基づいて治療法を調整する精密医療アプローチの採用により、患者固有のニーズに対応する標的IHD治療への新たな道が開かれつつあります。

最後に、予防ヘルスケアとリスク因子管理が重視されるようになったことが、IHD治療薬市場の成長に寄与しています。政府や医療機関は、生活習慣の改善、早期診断、高コレステロールや高血圧などの危険因子の効果的な管理を通じて、心血管疾患の発症率を低下させることを目的とした公衆衛生上の取り組みを実施しています。この予防的アプローチは、包括的な心血管治療戦略の一環として、脂質低下薬、抗高血圧薬、その他の心臓保護薬の使用を促進しています。さらに、ウェアラブルデバイスやモバイルヘルスアプリケーションなどのデジタルヘルス技術の統合により、心血管系の健康状態の継続的なモニタリングが可能になり、治療計画に対する患者のアドヒアランスが向上しています。これらの技術的進歩は、IHDの管理を強化し、合併症のリスクを低減し、患者の転帰を改善しています。心血管系の健康に対する世界の関心が高まり、新たな治療法が続々と登場する中、IHD治療薬市場は、技術革新、意識の高まり、より効果的で個別化された治療オプションの必要性によって、持続的な成長を遂げる態勢が整っています。

調査対象企業の例（注目の56社）

  • Amgen, Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Biocon Ltd.
  • Camber Pharmaceuticals, Inc.
  • Covis Pharma
  • Dr. Reddy's Laboratories Ltd.
  • Kowa Pharmaceuticals America, Inc.
  • Lupin Ltd.
  • Medicure, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP24392

Global Ischemic Heart Disease (IHD) Drugs Market to Reach US$7.2 Billion by 2030

The global market for Ischemic Heart Disease (IHD) Drugs estimated at US$6.1 Billion in the year 2023, is expected to reach US$7.2 Billion by 2030, growing at a CAGR of 2.4% over the analysis period 2023-2030. Angina Pectoris Drugs, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$4.3 Billion by the end of the analysis period. Growth in the Myocardial Infarction Drugs segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 4.8% CAGR

The Ischemic Heart Disease (IHD) Drugs market in the U.S. is estimated at US$1.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 4.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 1.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.

Global Ischemic Heart Disease (IHD) Drugs Market - Key Trends & Drivers Summarized

Why Are Ischemic Heart Disease (IHD) Drugs Becoming a Critical Focus in Cardiovascular Healthcare?

Ischemic Heart Disease (IHD), also known as coronary artery disease, remains one of the leading causes of morbidity and mortality worldwide, driving a significant demand for effective therapeutic solutions. IHD is characterized by reduced blood supply to the heart muscle, often caused by the buildup of plaque in the coronary arteries, leading to symptoms such as chest pain (angina), shortness of breath, and, in severe cases, heart attacks. The increasing prevalence of IHD, driven by factors such as aging populations, sedentary lifestyles, and the rising incidence of risk factors like hypertension, diabetes, and obesity, has positioned IHD drugs as a critical component of cardiovascular healthcare. As the global burden of IHD continues to grow, there is a heightened focus on developing and optimizing drug therapies that can effectively manage the disease, improve patient outcomes, and reduce the risk of life-threatening cardiac events.

The market for IHD drugs is expanding as healthcare systems across the world prioritize cardiovascular health. Key pharmaceutical treatments for IHD include antiplatelet agents, anticoagulants, beta-blockers, calcium channel blockers, nitrates, and lipid-lowering agents. These drugs aim to alleviate symptoms, prevent complications, and enhance the quality of life for patients. In recent years, there has been a surge in research and development activities targeting novel drug classes, such as PCSK9 inhibitors and GLP-1 receptor agonists, which offer additional therapeutic benefits by addressing underlying risk factors like high cholesterol and diabetes. The growing emphasis on personalized medicine is further influencing the IHD drug market, as treatment approaches are increasingly tailored to individual patient profiles based on genetic, biochemical, and lifestyle factors. As a result, the demand for more effective and individualized IHD therapies is driving innovation and growth in the global market.

What Technological and Pharmacological Innovations Are Shaping the Future of IHD Drugs?

Technological and pharmacological advancements are significantly transforming the landscape of IHD drug development, leading to the introduction of more effective and safer treatment options. One of the key innovations is the development of novel drug classes that target specific biological pathways associated with IHD. For instance, PCSK9 inhibitors such as alirocumab and evolocumab have emerged as groundbreaking lipid-lowering agents that significantly reduce LDL cholesterol levels in patients who are unresponsive to traditional statin therapy. By inhibiting the PCSK9 protein, these drugs enhance the liver’s ability to remove LDL cholesterol from the bloodstream, thereby lowering the risk of cardiovascular events. Another promising class of drugs is SGLT-2 inhibitors, originally developed for diabetes management, which have demonstrated cardioprotective effects in patients with IHD, reducing the risk of heart failure and myocardial infarction. These pharmacological advancements are broadening the range of therapeutic options available for managing IHD, enabling clinicians to adopt more comprehensive and targeted treatment strategies.

Additionally, advancements in drug delivery technologies are enhancing the efficacy and patient compliance of IHD medications. The use of extended-release formulations, transdermal patches, and combination therapies is helping to optimize drug absorption and reduce dosing frequency, thereby improving patient adherence to treatment regimens. Furthermore, the integration of artificial intelligence (AI) and machine learning in drug discovery and development is accelerating the identification of new therapeutic targets and the optimization of clinical trial designs. AI-driven platforms can analyze vast datasets to predict drug efficacy and safety profiles, enabling more efficient drug development processes. The use of pharmacogenomics is another emerging trend, as it allows for the identification of genetic markers that influence drug response, paving the way for personalized therapies tailored to the genetic makeup of individual patients. These technological and pharmacological innovations are not only advancing the field of IHD drug development but are also making treatments more effective, safer, and accessible to a broader patient population.

How Are Market Dynamics and Healthcare Policies Influencing the Ischemic Heart Disease Drugs Market?

The global market for ischemic heart disease drugs is being shaped by a combination of market dynamics and healthcare policies, which vary significantly across regions. The increasing prevalence of IHD, particularly in developed regions like North America and Europe, where aging populations and lifestyle-related risk factors are prevalent, is a major driver of market growth. The demand for IHD drugs is also rising in emerging markets such as Asia-Pacific and Latin America, where economic development, urbanization, and changes in dietary habits are contributing to a growing burden of cardiovascular diseases. In response to these trends, pharmaceutical companies are expanding their presence in these regions, investing in local production facilities, and partnering with regional healthcare providers to improve access to IHD medications.

Healthcare policies and reimbursement frameworks are also playing a critical role in shaping the IHD drugs market. In many countries, the cost of IHD drugs is covered by public or private insurance programs, making these therapies more accessible to patients. However, the rising cost of newer therapies, particularly biologics and specialty drugs, has raised concerns about affordability and access. In regions with stringent healthcare budgets, such as Europe, governments and health agencies are implementing cost-containment measures, including price negotiations, reference pricing, and the promotion of generic and biosimilar alternatives. These policies are influencing the pricing strategies of pharmaceutical companies and driving the adoption of cost-effective treatment options. Additionally, regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are emphasizing the importance of clinical evidence and real-world data to support the approval and reimbursement of new IHD therapies. This regulatory landscape is pushing companies to conduct more rigorous clinical trials and post-marketing studies, ensuring that new drugs offer meaningful benefits over existing treatments.

The push towards value-based healthcare is another factor impacting the IHD drugs market. Health systems are increasingly focusing on outcomes-based approaches that prioritize treatments demonstrating superior efficacy, safety, and cost-effectiveness. This shift is encouraging pharmaceutical companies to invest in long-term clinical trials and health economics studies to demonstrate the value of their products. Moreover, the growing emphasis on preventive healthcare and risk factor management is shaping the development of IHD therapies that not only treat the disease but also address underlying conditions such as hypertension, diabetes, and high cholesterol. These market dynamics and policy trends are creating both challenges and opportunities for the IHD drugs market, as stakeholders seek to balance innovation with cost containment and access to care.

What Are the Key Growth Drivers Fueling the Expansion of the Ischemic Heart Disease Drugs Market?

The growth in the global ischemic heart disease (IHD) drugs market is driven by several key factors, including the increasing prevalence of cardiovascular diseases, the development of novel drug therapies, and the growing focus on personalized and preventive medicine. One of the primary growth drivers is the rising incidence of IHD, which is closely linked to risk factors such as obesity, diabetes, hypertension, and sedentary lifestyles. The global burden of IHD is expected to continue rising as populations age and lifestyle-related diseases become more prevalent. This growing patient pool is driving the demand for effective IHD therapies that can manage symptoms, prevent complications, and reduce the risk of acute events such as heart attacks. Moreover, the increasing awareness of cardiovascular health and the importance of early intervention are encouraging more individuals to seek medical advice and adhere to prescribed treatments, further boosting the demand for IHD drugs.

Another significant growth driver is the ongoing development and commercialization of novel drug therapies that offer new mechanisms of action and improved safety profiles. Recent advances in the understanding of the pathophysiology of IHD have led to the development of innovative drugs that target specific molecular pathways involved in the disease. For instance, the introduction of PCSK9 inhibitors and SGLT-2 inhibitors has expanded the therapeutic landscape for managing IHD, providing options for patients who are not adequately controlled with conventional therapies. The development of combination therapies that target multiple pathways simultaneously is also gaining traction, as these therapies can offer enhanced efficacy and convenience compared to monotherapies. Furthermore, the adoption of precision medicine approaches, which tailor treatments based on individual genetic and clinical profiles, is opening new avenues for targeted IHD therapies that address the unique needs of each patient.

Lastly, the increasing emphasis on preventive healthcare and risk factor management is contributing to the growth of the IHD drugs market. Governments and healthcare organizations are implementing public health initiatives aimed at reducing the incidence of cardiovascular diseases through lifestyle modifications, early diagnosis, and effective management of risk factors such as high cholesterol and hypertension. This preventive approach is driving the use of lipid-lowering agents, antihypertensives, and other cardioprotective drugs as part of comprehensive cardiovascular care strategies. Additionally, the integration of digital health technologies, such as wearable devices and mobile health applications, is enabling continuous monitoring of cardiovascular health and facilitating better patient adherence to treatment plans. These technological advancements are enhancing the management of IHD, reducing the risk of complications, and improving patient outcomes. As the global focus on cardiovascular health intensifies and as new therapies continue to emerge, the IHD drugs market is poised for sustained growth, driven by innovation, increased awareness, and the need for more effective and personalized treatment options.

Select Competitors (Total 56 Featured) -

  • Amgen, Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Biocon Ltd.
  • Camber Pharmaceuticals, Inc.
  • Covis Pharma
  • Dr. Reddy's Laboratories Ltd.
  • Kowa Pharmaceuticals America, Inc.
  • Lupin Ltd.
  • Medicure, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Ischemic Heart Disease (IHD) Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Cardiovascular Diseases Propels Demand for Ischemic Heart Disease (IHD) Drugs
    • Increasing Focus on Preventive Cardiovascular Care Expands Addressable Market for IHD Drugs
    • Case Overview: Growth in Geriatric Population Bodes Well for IHD Drug Market Expansion
    • Increasing Demand for Combination Therapies Expands Market Scope for IHD Treatments
    • Rising Healthcare Expenditure in Emerging Markets Expands Addressable Market for IHD Drugs
    • Case Overview: Rising Adoption of Telemedicine and Remote Monitoring for Cardiovascular Health Expands Market Reach
    • Technological Innovations in Cardiovascular Devices and Drug-Eluting Stents Propel Market Integration
    • Technological Advancements in Extended-Release and Long-Acting IHD Drugs Propel Market Innovation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Ischemic Heart Disease (IHD) Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Ischemic Heart Disease (IHD) Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Angina Pectoris by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Angina Pectoris by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Angina Pectoris by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Myocardial Infarction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Myocardial Infarction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Myocardial Infarction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Ischemic Heart Disease (IHD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • JAPAN
    • Ischemic Heart Disease (IHD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • CHINA
    • Ischemic Heart Disease (IHD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: China 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • EUROPE
    • Ischemic Heart Disease (IHD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Ischemic Heart Disease (IHD) Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • FRANCE
    • Ischemic Heart Disease (IHD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: France 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • GERMANY
    • Ischemic Heart Disease (IHD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Ischemic Heart Disease (IHD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Ischemic Heart Disease (IHD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Ischemic Heart Disease (IHD) Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Ischemic Heart Disease (IHD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • INDIA
    • Ischemic Heart Disease (IHD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: India 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Ischemic Heart Disease (IHD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Ischemic Heart Disease (IHD) Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Ischemic Heart Disease (IHD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Ischemic Heart Disease (IHD) Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030
  • AFRICA
    • Ischemic Heart Disease (IHD) Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Ischemic Heart Disease (IHD) Drugs by Disease Class - Angina Pectoris and Myocardial Infarction Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Ischemic Heart Disease (IHD) Drugs by Disease Class - Percentage Breakdown of Value Sales for Angina Pectoris and Myocardial Infarction for the Years 2014, 2024 & 2030

IV. COMPETITION